The downstream processing market size at $21.8 billion in 2020, and is projected to reach $92.0 billion by 2030, growing at a CAGR of 13.5% from 2021 to 2030. The downstream processing is defined as purification and recovery of biosynthetic products, mainly pharmaceuticals, from natural sources such as fermentation broth, plant tissues and animal tissues, including the recycling of salvageable components and the proper treatment and disposal of waste. It is an important stage in the production of pharmaceuticals such as hormones, vaccines (e.g. insulin and human growth hormone), antibodies (e.g. infliximab & abciximab) & antibiotics; enzymes antibodies used in diagnostics; industrial enzymes; flavor and natural fragrance compounds.
The key factors that drive the downstream processing industry growth include increase in demand for biopharmaceuticals and rise in R&D expenditure for biopharmaceutical companies. Furthermore, increase in usage of membrane filtration in sterilization, and importance of concentration processes to produce biopharmaceuticals and vaccines are the key factors expected to downstream processing market growth. In addition, increased demands for new solutions, process optimization & cost reduction, and growth in use of techniques such as centrifuge, to separate biological particles from suspension further fuel the downstream processing market. However, dearth and shortage of skilled bioprocess engineers restrain the market growth. Moreover, emerging markets such as China and India, offer downstream processing market opportunity.
The downstream processing market analysis on the basis of technique, product, system, application, end user, and region. By technique, it is categorized into purification, separation, and clarification/concentration. depending on product, it is classified into chromatography columns and resins, filters, membrane absorbers, and other products. By system, it is bifurcated into single use system and re-usable system. By application, it is divided into monoclonal antibody production, vaccine production, insulin production, immunoglobulin production, erythropoietin production, and other applications. By end user, it is categorized into biopharmaceutical manufacturers, and contract manufacturing organizations (CMOs). By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Depending on the technique, the purification segment was the highest contributor to the market in 2020, and this trend is expected to continue during the forecast period, due to the high need of pure biopharmaceutical products to meet the regulatory standards, as downstream purification plays a significant role in enhancing the quality and purity of products.
By product, the chromatography columns and resins segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to an increase in adoption of single-use chromatography systems, rise in R&D, and speed of chromatography systems.
By application, the monoclonal antibody production segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to the increase in the prevalence of cancer across the world and the adoption of advanced technology in downstream purification technology to develop high-quality products such as monoclonal antibodies at a lower cost.
By End User
Biopharmaceutical Manufacturers segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.
By end-user, the biopharmaceutical manufacturers segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to an increase in demand for biopharmaceuticals across the world for the treatment of various diseases.
Region-wise, North America has highest downstream processing market share in 2020 and is expected to be dominant during the forecast period, owing to an increase in government support for promoting bioprocess technology, developed healthcare infrastructure and a rise in medical expenditure in this region.
However, Asia-Pacific is expected to register highest CAGR from 2021 to 2030, owing to an increase in investment in the field of biotechnology and presence of large patient pool, which accelerates the need of advanced medical technologies to develop biopharmaceuticals for the treatment of various disease.
The key players operating in the downstream processing industry include, 3M Company, Sartorius Stedim Biotech S.A, Danaher Corporation, Thermo Fisher Scientific Inc, Merck & Co., Inc., Boehringer Ingelheim, Lonza Group AG, Eppendorf AG, Finesse Solutions, Inc. and Repligen Corporation.
The downstream processing market is segmented into Technology, Product, System, Application and End User.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of theDownstream Processing Market Size analysis from 2020 to 2030 to identify the prevailing downstream processing market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the downstream processing market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global downstream processing market trends, key players, market segments, application areas, and market growth strategies.
Downstream Processing Market Report Highlights
By End User
Key Market Players
Religen Inc, Agilent Technologies Inc., 3M Company, Sartorius Stedim Biotech S.A, Bio Rad Laboratories, Inc, Merck KGaA., Lonza Group AG, Eppendorf AG, Marathon Petroleum Corporation, Thermo Fisher Scientific Inc.
This section provides the opinions of top level CXOs in the downstream processing market. According to them, downstream processing is used to isolate, purify and concentrate the drug substance. Downstream processing also involves harvesting and clarification steps to remove bulk contaminants such as particulates, carbohydrates, and oils followed by capturing and polishing steps that refine the feed stream until only the target product remains.
As per the analysts, rise in incidence of chronic diseases, technological advancements, and increase in demand of biopharmaceuticals are some of the major factors that drive this market. In addition, increase in prevalence of chronic diseases such as cancer, genetic disorders, and rare diseases among others, has increased the demand for vaccines and antibodies production, which is expected to drive the growth of the market in upcoming years. However, dearth of experienced bioprocessing engineers hampers the market growth.
Furthermore, by region, North America is expected to remain dominant during the forecast period, due to local presence of large in-house biopharmaceutical manufacturing facilities. Asia-Pacific registered highest CAGR and is expected to continue this trend throughout the forecast period, owing to rise in expenditure on healthcare & improvement in the medical and healthcare infrastructure.